Comorbidities associated with psoriatic arthritis compared with non-psoriatic spondyloarthritis: A cross-sectional study

Journal of Rheumatology

Volumn 43, Issue 2, 2016, Pages 376-382

  Haque, Naba ^a,b   Lories, Rik J ^a,b   De Vlam, Kurt ^a,b  

^a SKELETAL BIOLOGY AND ENGINEERING RESEARCH CENTER   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Ankylosing spondylitis; Comorbidities; Psoriatic arthritis; Spondyloarthritis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLADDER CANCER; BREAST CANCER; CEREBROVASCULAR ACCIDENT; COLON ADENOCARCINOMA; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DISEASE DURATION; EDUCATIONAL STATUS; EMPLOYMENT STATUS; FEMALE; GOUT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE RHEUMATOID ARTHRITIS; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MESOTHELIOMA; METABOLIC SYNDROME X; MIDDLE AGED; NONHODGKIN LYMPHOMA; OROPHARYNX CARCINOMA; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; PSORIATIC ARTHRITIS; SAPHO SYNDROME; SEX RATIO; SPONDYLARTHRITIS; UTERINE CERVIX CARCINOMA; AGED; ARTHRITIS, PSORIATIC; CARDIOVASCULAR DISEASES; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; FACTUAL DATABASE; HYPERLIPIDEMIAS; YOUNG ADULT;

ADULT; AGED; ARTHRITIS, PSORIATIC; CARDIOVASCULAR DISEASES; COMORBIDITY; CROSS-SECTIONAL STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERLIPIDEMIAS; INCIDENCE; MALE; MIDDLE AGED; SPONDYLARTHRITIS; YOUNG ADULT;

EID: 84969389432     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.141359     Document Type: Article

References (49)

1. Scarpa R, Ayala F, Caporaso N, Olivieri I. Psoriasis, psoriatic arthritis, or psoriatic disease? J Rheumatol 2006;33:210-2.
2. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361:496-509.
3. Haroon M, Fitzgerald O. Pathogenetic overview of psoriatic disease. J Rheumatol Suppl. 2012 Jul;89:7-10.
4. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64 Suppl 2:ii14-7.
5. Nash P, Mease PJ, Braun J, van der Heijde D. Seronegative spondyloarthropathies: to lump or split? Ann Rheum Dis 2005;64 Suppl 2:ii9-13.
6. Dougados M, Baeten D. Spondyloarthritis. Lancet 2011; 377:2127-37.
7. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005;64 Suppl 2:ii18-23.
8. Scarpa R. New insights into the concept of psoriatic disease. J Rheumatol Suppl. 2012 Jul;89:4-6.
9. Boehncke WH, Boehncke S, Schön MP. Managing comorbid disease in patients with psoriasis. BMJ 2010;340:b5666.
10. Daudén E, Castañeda S, Suárez C, García-Campayo J, Blasco AJ, Aguilar MD, et al; Working Group on Comorbidity in Psoriasis. Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. J Eur Acad Dermatol Venereol 2013;27:1387-404.
11. Husni ME, Mease PJ. Managing comorbid disease in patients with psoriatic arthritis. Curr Rheumatol Rep 2010;12:281-7.
12. Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol 2010;163:586-92.
13. Arumugam R, McHugh NJ. Mortality and causes of death in psoriatic arthritis. J Rheumatol Suppl. 2012 Jul;89:32-5.
14. Buckley C, Cavill C, Taylor G, Kay H, Waldron N, Korendowych E, et al. Mortality in psoriatic arthritis-a single-center study from the UK. J Rheumatol 2010;37:2141-4.
15. Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009;68:1131-5.
16. Kimki O, Caspi D, Bornstein NM, Maharshak N, Gur A, Arbel Y, et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 2007;36:203-9.
17. Tam LS, Tomlinson B, Chu TT, Li M, Leung YY, Kwok LW, et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls-the role of inflammation. Rheumatology 2008;47:718-23.
18. Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006;33:2167-72.
19. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens 2013; 31:433-42.
20. Gelfand JM, Yeung H. Metabolic syndrome in patients with psoriatic disease. J Rheumatol Suppl. 2012 Jul;89:24-8.
21. Armstrong AW, Schupp C, Bebo B. Psoriasis comorbidities: results from the National Psoriasis Foundation surveys 2003 to 2011. Dermatology 2012;225:121-6.
22. Haroon M, Gallagher P, Heffernan E, FitzGerald O. High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease. J Rheumatol 2014;41:1357-65.
23. Cohen AD, Dreiher J, Shapiro Y, Vidavsky L, Vardy DA, Davidovici B, et al. Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol 2008;22:585-9.
24. Vena GA, Altomare G, Ayala F, Berardesca E, Calzavara-Pinton P, Chimenti S, et al. Incidence of psoriasis and association with comorbidities in Italy: a 5-year observational study from a national primary care database. Eur J Dermatol 2010;20:593-8.
25. Love TJ, Zhu Y, Zhang Y, Wall-Burns L, Ogdie A, Gelfand JM, et al. Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis 2012;71:1273-7.
26. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C; American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8.
27. Khraishi M, Aslanov R, Rampakakis E, Pollock C, Sampalis JS. Prevalence of cardiovascular risk factors in patients with psoriatic arthritis. Clin Rheumatol 2014;33:1495-500.
28. Boehncke WH, Boehncke S, Tobin AM, Kirby B. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011;20:303-7.
29. Jamnitski A, Symmons D, Peters MJ, Sattar N, McInnes I, Nurmohamed MT. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis 2013;72:211-6.
30. Olsen JH, Møller H, Frentz G. Malignant tumors in patients with psoriasis. J Am Acad Dermatol 1992;27:716-22.
31. Ishioka S, Maeda A, Jougasaki Y, Hiyama K, Yamakido M. Psoriatic arthritis complicating lung cancer. Intern Med 2000;39:185-7.
32. Rohekar S, Tom BD, Hassa A, Schentag CT, Farewell VT, Gladman DD. Prevalence of malignancy in psoriatic arthritis. Arthritis Rheum 2008;58:82-7.
33. Westhovens I, Lories RJ, Westhovens R, Verschueren P, de Vlam K. Anti-TNF therapy and malignancy in spondyloarthritis in the Leuven spondyloarthritis biologics cohort (BIOSPAR). Clin Exp Rheumatol 2014;32:71-6.
34. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34:1218-27.
35. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
36. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73.
37. PubMed Health. Metabolic syndrome. [Internet. Accessed October 28, 2015.]. Available from: www.ncbi.nlm.nih.gov/pubmedhealth/PMH0004546
38. Husted JA, Thavaneswaran A, Chandran V, Eder L, Rosen CF, Cook RJ, et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res 2011;63:1729-35.
39. Dreiher J, Freud T, Cohen AD. Psoriatic arthritis and diabetes: a population-based cross-sectional study. Dermatol Res Pract 2013;2013:580404.
40. Dubreuil M, Rho YH, Man A, Zhu Y, Zhang Y, Love TJ, et al. Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study. Rheumatology 2014;53:346-52.
41. Favarato MH, Mease P, Gonçalves CR, Gonçalves Saad C, Sampaio-Barros PD, Goldenstein-Schainberg C. Hypertension and diabetes significantly enhance the risk of cardiovascular disease in patients with psoriatic arthritis. Clin Exp Rheumatol 2014;32:182-7.
42. Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015;74:480-9.
43. Sattar N, Crompton P, Cherry L, Kane D, Lowe G, McInnes IB. Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 2007;56:831-9.
44. Kristensen LE, Englund M, Neovius M, Askling J, Jacobsson LT, Petersson IF. Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: a population-based regional Swedish cohort study. Ann Rheum Dis 2013;72:1675-9.
45. Naranjo A, Sokka T, Descalzo MA, Calvo-Alén J, Hørslev-Petersen K, Luukkainen RK, et al; QUEST-RA Group. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008;10:R30.
46. Liu Y, Helms C, Liao W, Zaba LC, Duan S, Gardner J, et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 2008;4:e1000041.
47. Sharma N, Tripathi P, Awasthi S. Role of ADAM33 gene and associated single nucleotide polymorphisms in asthma. Allergy Rhinol 2011;2:e63-70.
48. Wolf N, Quaranta M, Prescott NJ, Allen M, Smith R, Burden AD, et al. Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. J Med Genet 2008;45:114-6.
49. Haupt A, Guthoff M, Gallwitz B, Haring HU, Fritsche A. Variation in the CDKAL1 gene is associated with the titer of antibodies to GAD. Diabetes Care 2008;31:e66.